《即日市評》恆指再跌 港交所挫逾半成創新低
受友邦(01299.HK)、騰訊(00700.HK)及港交所(00388.HK)弱勢拖累,恆指今日(5日)持續向下,再創年內低位。美國國債孳息率回升,美股道指及納指隔晚(4日)各跌0.11%及0.8%,撰文之時,美國10年期債券跌至4.253厘,美匯指數升至103.68,道指期貨最新跌64點或0.18%,納指期貨最新跌0.5%。上證綜指全日跌50點或1.7%收2,972點,失守3,000點關,深證成指跌2%,而滬深兩市成交額共8,225億人民幣。。
恆指低開39點後跌幅擴大,午後曾跌417點一度低見16,228點,尾市跌幅稍為收窄,全日跌318點或1.9%,收16,327點;國指全日跌93點或1.6%,收5,609點;恆生科技指數跌77點或2.1%,收3,682點。大市全日成交總額1,180.25億元,滬、深港通南下交易淨流入31.92億及29.49億元人民幣。友邦全日股價跌4%,港交所全日股價下挫5.5%收253.6元創新低。聯想集團(00992.HK)股價急跌10.2%。
就評級機構穆迪調低中國主權評級展望至「負面」,中國財政部表示,對此感到失望,指預計第四季度中國經濟將保持回升向好態勢,指房地產市場下行對地方一般公共預算和政府性基金預算帶來的影響是可控的。
【港交所捱沽 聯想挫一成】
科技股方面,內地11月共批87款國產網絡遊戲,網易-S(09999.HK)「世界之外」在列,網易全日股價跌5.2%。阿里-SW(09988.HK)跌0.4%報70.5元,騰訊跌2.5%、美團-W(03690.HK)下滑近2.1%、快手-W(01024.HK)跌1.8%,小米-W(01810.HK)跌2.9%。
摩根士丹利發表報告指,內地科網股今年輕微跑贏內地股市,但個別股份表現分化,認為明年仍然受制於宏觀因素疲弱,由非市場風險主導個別股份表現,市場關注內容具有適應能力的龍頭股份、具有獨特增長潛力及人工智能概念的股份。當中遊戲及音樂內容供應商,例如網易(NTES.US)、騰訊及騰訊音樂(TME.US)繼續展現韌性。同時關注在本地或海外市場具有獨特增長機會的拼多多(PDD.US),教育股新東方(EDU.US)及好未來(TAL.US)。人工智能緩慢地應用,不過仍然認為百度(BIDU.US)具有建設意義。
【跌股千三隻 藥明系續弱】
港股主板今日市寬轉差,主板股票的升跌比率為11比32(上日為14比28),下跌1,325隻(跌幅3.1%),恆指成份股今日10隻股份上升,69隻股份下跌,升跌比率為12比84(上日為33比61);大市今日錄沽空249.39億元,佔可沽空股份成交額1,019.39億元的24.464%(上日17.899%)。
藥明生物(02269.HK)今日復牌挫8.4%收30.35元,藥明康德(02359.HK)續跌2.9%,藥明合聯(02268.HK)下滑4.4%。交銀國際發表報告指,藥明生物核心業務增速下滑,公司下調今明年收入和利潤指引。公司料今年剔除新冠項目後收入預計增速36%,但整體收入增速預計僅為10%,大幅低於此前30%的指引。利潤方面,全球基地產能爬坡導致今年毛利損失1億美元,公司預計今年毛利率約40%,淨利潤與去年基本持平,經調整淨利潤小幅下滑。
交銀國際下調藥明生物目標價至34元。根據公司最新指引及行業實際訂單情況,下調公司今年至後年各年收入預測14%至24%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.